Programme

9:00-9:10 – opening

Session 1: Genetic and cell therapies. Chair: Józef Dulak

09:10-09:30 – Seppo Yla-Herttuala (Kuopio, Finland) – Gene therapy of cardiovascular diseases

09:30-09:50 – Giulio Cossu (Manchester, UK)– Cell-mediated exon skipping for the cell therapy of DMD

09:50-10:10 – Markus Ruegg (Basel, Switzerland) - Gene therapeutic strategies to treat an early-onset muscular dystrophy

10:10-10:30 – discussion

10:30-11:00 – break

Session 2: Hematopoietic and immune-cells based therapies. Chair: Agnieszka Łoboda

11:00-11:20 – Alicja Józkowicz (Kraków, Poland) - Mobilization of neutrophils and hematopoietic progenitors - how to induce endogenous G-CSF?"

11:20-11:40 – Piotr Trzonkowski (Gdańsk, Poland) - T regulatory cells as drugs – development and challenges

11:40-12:00 – Dominika Nowis (Warszawa, Poland) - Arginases and anti-tumor immune response

12:00-12:30 – discussion

12:30-13:00 – break

Session 3: Novel challenges, possibilities, hopes and hypes. Chair: Tomasz Twardowski

13:00-13:20 – Krzysztof Pyrć (Kraków, Poland) - Novel SARS-CoV-2 antivirals

13:20-13:40 – Pamela Robey (Bethesda, USA) – Treatment of COVID-19 with “MSCs” – magic bullet or snake oil?

13:40-14:00 – Józef Dulak (Kraków, Poland)– Induced pluripotent stem cells for cardiovascular disease modeling and therapy.

14:00-14:40 – discussion (with speakers of all sessions)

Session 4: Moderated poster session

14:40-16:30 – (5 min talk – 3 min plus 2 min questions)